Athira Pharma ATHA 深 沪
已收盘 08-01 16:00:00 美东时间
0.3702
-0.010
-2.58%
华盛通- 最 高0.3784
- 今 开0.34
- 成交量 34.88万股
- 最 低 0.3236
- 昨 收 0.38
- 总市值 1445.35万
- 52周最高 3.67
- 市盈率 静 --
- 换手率 0.89%
- 52周最低 0.2195
- 委 比 99.58%
- 总股本 3904.24万
- 历史最高 34.79
- 量 比 1.68
- 振 幅 14.42%
- 历史最低 0.2195
- 每 手 1
- 风险率 0.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Athena Gold Boosts Visibility with New Marketing Agreements
Athena Gold ( ($TSE:ATHA) ) has provided an update. Athena Gold Corporation has...
07-04 22:07
ATHA Energy Unveils Promising Uranium Discoveries in Angikuni Basin
Atha Energy Corp. ( ($TSE:SASK) ) has provided an announcement. ATHA Energy Cor...
06-24 20:11
ATHA Energy Strengthens Board with Industry Veteran Appointment
An announcement from Atha Energy Corp. ( ($TSE:SASK) ) is now available. ATHA E...
05-14 20:19
Athira Pharma To Present Data From Phase 1 Clinical Trial Of ATH-1105 In Healthy Volunteers At 4Th Annual ALS Drug Development Summit
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical developmentOn-track
05-13 23:02
Athira Pharma Reports Reduced Losses and Strategic Focus
Athira Pharma, Inc. ( ($ATHA) ) has released its Q1 earnings. Here is a breakdo...
05-10 12:16
Athira Pharma Q1 EPS $(0.23) Up From $(0.69) YoY
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.23) per share. This is a 66.67 percent increase over losses of $(0.69) per share from the same period last year.
05-10 04:08
Athira Pharma (ATHA) Gets a Hold from JMP Securities
JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (...
02-28 14:26
Terns Pharmaceuticals appoints new CFO
Terns Pharmaceuticals (NASDAQ:TERN) announced the appointment of Andrew Gengos as chief financial officer, effective immediately. Gengos most recently, served as the chief financial officer of Athira ...
02-25 05:20
Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a statistically significant impact in a mid-stage trial for patients with multi...
01-30 21:32
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct
Unity Software(U.US) reported fourth-quarter financial results after the market...
01-07 06:58
